

# Real-world evaluation of a novel, adhesion device for the prevention of post-operative bleeding

<b>Submission date</b> 20/06/2023	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 26/06/2023	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 13/11/2025	<b>Condition category</b> Surgery	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Haemostats are medical devices used by surgeons to stop bleeding during procedures and also to prevent bleeding restarting after the procedure has been completed. Not all haemostats stick to the bleeding site and so are less effective at preventing post-operative bleeding. Many of the haemostats that can adhere to the bleeding site use biological or chemical agents to achieve this. This study aims to evaluate a new haemostat (TenaTac) that avoids the use of biologic or chemical agents.

### Who can participate?

Patients undergoing planned surgery at one of the participating hospitals if their surgeon is part of the evaluation group

### What does the study involve?

During surgery, if the surgeon needs to use a haemostat and chooses to use TenaTac, then on completion of the surgery the surgeon will complete a structured questionnaire about how well the TenaTac performed.

### What are the possible benefits and risks of participating?

The benefits are that the patient will avoid exposure to the biological or chemical agents used in alternative haemostats. The risks are that the TenaTac doesn't perform as well as another haemostat.

### Where is the study run from?

St John's Innovation Centre, Cambridge, UK.

### When is the study starting and how long is it expected to run for?

January 2020 to December 2025.

### Who is funding the study?

The co-sponsors of the study are Selentus Science (UK) and CuraMedrix (Netherlands).

Who is the main contact?  
Mr Paul Hayes MD FRCS, phayes@selentus.com

## Contact information

### Type(s)

Public

### Contact name

Mr Paul Hayes

### ORCID ID

<https://orcid.org/0000-0002-1968-5930>

### Contact details

BioCity, 1 Thoresby Street  
Nottingham  
United Kingdom  
NG1 1GF  
+44 1159124210  
enquiry@selentus.com

### Type(s)

Scientific

### Contact name

Mr Paul Hayes

### Contact details

Biocity, 1 Thoresby Street  
Nottingham  
United Kingdom  
NG1 1GF  
+44 1159124210  
phayes@selentus.com

### Type(s)

Principal investigator

### Contact name

Mr Paul Hayes

### Contact details

BioCity, 1 Thoresby Street,  
Nottingham  
United Kingdom  
NG1 1GF  
+44 1159124210  
phayes@selentus.com

# Additional identifiers

## Clinical Trials Information System (CTIS)

Nil known

## ClinicalTrials.gov (NCT)

Nil known

## Protocol serial number

Cura PMCF 1

# Study information

## Scientific Title

Real-world, post-market clinical study of the intra-procedural performance of a novel adhesive haemostat across six surgical specialities

## Study objectives

A novel adherent haemostat using only a simple physical modification of its surface would adhere adequately to tissues, and effect haemostasis on a bleeding surgical site to the satisfaction of the operating surgeon.

## Ethics approval required

Ethics approval not required

## Ethics approval(s)

The study is a post-market clinical follow up of a CE-marked medical device being used within its Indication for Use. The choice of which haemostat to treat the patient with was at the discretion of the surgeon and no mandating of treatment occurred. No patient data was shared, only information relating to the general type of surgery and the performance of the device.

## Study design

Observational case series

## Primary study design

Observational

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Treatment of haemorrhage in surgical patients

## Interventions

A novel haemostat using only a physical modification of the device surface to affect adhesion was evaluated by multiple surgeons, across 6 surgical specialities. A structured questionnaire relating to the device performance was completed by the surgeon at the end of the procedure.

The application of a haemostat to the bleeding site. No control agent is planned. The adherence of the haemostat to the tissue surface will be graded 1 to 5 by the surgeon, as will the efficacy of haemostasis obtained.

**Intervention Type**

Device

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

TenaTac

**Primary outcome(s)**

The effectiveness of haemostasis graded from 1 (unacceptable) to 5 (excellent) by the operating surgeon at the end of the procedure.

**Key secondary outcome(s)**

1. The effectiveness of adhesion graded from 1 (unacceptable) to 5 (excellent) by the operating surgeon at the end of the procedure.
2. The ease of use of the haemostat graded from 1 (unacceptable) to 5 (excellent) by the operating surgeon at the end of the procedure.
3. Binary response to whether the surgeon would use the product again during surgery

**Completion date**

31/12/2025

**Eligibility****Key inclusion criteria**

1. Patient undergoing elective surgery
2. Patient greater than 16 years of age
3. Able to give informed consent
4. Willing to complete study procedures and attend for follow-up visit

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Mixed

**Lower age limit**

16 years

**Upper age limit**

100 years

**Sex**

All

**Total final enrolment**

0

**Key exclusion criteria**

1. Presence of a documented disorder of coagulation
2. An INR >2.0 within 12h of surgery (if measured)
3. Allergy to porcine products
4. Use of dual anti-platelets within 3 days of surgery
5. Oral anti-coagulant use within 24h of surgery
6. Enrolment in another clinical study that might reasonably interfere with this study's end-points
7. Member of a vulnerable group of adults or life expectancy less than one year.

**Date of first enrolment**

14/01/2020

**Date of final enrolment**

01/11/2025

**Locations****Countries of recruitment**

United Kingdom

England

Belgium

Croatia

Denmark

France

Germany

Netherlands

Serbia

Sweden

**Study participating centre**

**St John's Innovation Centre**

Cowley Road

Cambridge  
England  
CB4 0WS

**Study participating centre**  
**Dept of Neurosurgery**  
Antwerp University Hospital (UZA)  
Antwerp  
Belgium  
2650

## Sponsor information

**Organisation**  
Selentus Science

## Funder(s)

**Funder type**  
Industry

**Funder Name**  
Selentus Science

## Results and Publications

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**  
Not expected to be made available

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes